18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies

Abstract Among individuals with dementia with Lewy bodies, pathologic correlates of clinical course include the presence and extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease. The objectives of this study are to determine (i) whether 18F-fluorodeoxyglucose PET signature patterns of dementia with Lewy bodies are associated with the extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease and (ii) whether these 18F-fluorodeoxyglucose pattern(s) are associated with clinical course in dementia with Lewy bodies. Two groups of participants were included: a pathology-confirmed subset with Lewy body disease (n = 34) and a clinically diagnosed group of dementia with Lewy bodies (n = 87). A subset of the clinically diagnosed group was followed longitudinally (n = 51). We evaluated whether 18F-fluorodeoxyglucose PET features of dementia with Lewy bodies (higher cingulate island sign ratio and greater occipital hypometabolism) varied by Lewy body disease subtype (transitional versus diffuse) and Braak neurofibrillary tangle stage. We investigated whether the PET features were associated with the clinical trajectories by performing regression models predicting Clinical Dementia Rating Scale Sum of Boxes. Among autopsied participants, there was no difference in cingulate island sign or occipital hypometabolism by Lewy body disease type, but those with a lower Braak tangle stage had a higher cingulate island sign ratio compared to those with a higher Braak tangle stage. Among the clinically diagnosed dementia with Lewy bodies participants, a higher cingulate island ratio was associated with better cognitive scores at baseline and longitudinally. A higher 18F-fluorodeoxyglucose PET cingulate island sign ratio was associated with lower Braak tangle stage at autopsy, predicted a better clinical trajectory in dementia with Lewy body patients and may allow for improved prognostication of the clinical course in this disease.

[1]  Alan J. Thomas,et al.  Neuropathological Changes in Dementia With Lewy Bodies and the Cingulate Island Sign , 2019, Journal of neuropathology and experimental neurology.

[2]  J. Trojanowski,et al.  Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders , 2018, Annals of neurology.

[3]  J. Graff‐Radford,et al.  The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies , 2018, Alzheimer's & Dementia.

[4]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[5]  Clifford R. Jack,et al.  THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN , 2017, Alzheimer's & Dementia.

[6]  H. Matsuda,et al.  Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer’s disease using brain perfusion SPECT , 2017, Annals of Nuclear Medicine.

[7]  David T. Jones,et al.  Duration and Pathologic Correlates of Lewy Body Disease , 2017, JAMA neurology.

[8]  T. Montine,et al.  Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis , 2017, The Lancet Neurology.

[9]  W. M. van der Flier,et al.  Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  David T. Jones,et al.  Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry , 2016, Movement disorders : official journal of the Movement Disorder Society.

[11]  M. Kameyama,et al.  Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies , 2016, Annals of Nuclear Medicine.

[12]  Matthew L Senjem,et al.  Dementia with Lewy bodies , 2014, Neurology.

[13]  D. Aarsland,et al.  Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia , 2014, International journal of geriatric psychiatry.

[14]  C. Jack,et al.  Multimodality imaging characteristics of dementia with Lewy bodies , 2012, Neurobiology of Aging.

[15]  C. Jack,et al.  Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. , 2012, Brain : a journal of neurology.

[16]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[17]  Ronald C Petersen,et al.  Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. , 2011, Sleep medicine.

[18]  Arno Klein,et al.  A reproducible evaluation of ANTs similarity metric performance in brain image registration , 2011, NeuroImage.

[19]  C. Rowe,et al.  The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies , 2009, Journal of Nuclear Medicine.

[20]  R. Petersen,et al.  Validation of the Neuropathologic Criteria of the Third Consortium for Dementia With Lewy Bodies for Prospectively Diagnosed Cases , 2008, Journal of neuropathology and experimental neurology.

[21]  J. Morris,et al.  Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease , 2006, Neurology.

[22]  D W Dickson,et al.  DLB fluctuations , 2004, Neurology.

[23]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[24]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[25]  L. Thal,et al.  Cognitive decline is faster in Lewy body variant than in Alzheimer's disease , 1998, Neurology.

[26]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[27]  J. Morris The Clinical Dementia Rating (CDR) , 1993, Neurology.

[28]  D. Greenblatt,et al.  The International Classification of Sleep Disorders , 1992 .

[29]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[30]  J. Duchek,et al.  Mild senile dementia of the alzheimer type: 2. Longitudinal assessment , 1988, Annals of neurology.

[31]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.